Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test / MedCity

Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

---

Tuesday, February 17, 2026, 9:22 pm / permalink 19334 / 3 stories in 21 days

Related Stories

---

• FDA lifts holds on Intellia’s Phase 3 gene-editing trials / 4 days
• FDA rejects Disc Medicine’s rare-disease drug despite priority review / 18 days
• BridgeBio’s dwarfism drug posts positive Phase 3 data, FDA filing on track / 25 days
• FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval / 4 wks
• FDA Accepts Summit Therapeutics' Ivonescimab BLA for EGFR‑Mutant NSCLC / 5 wks
• FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
• FDA rejects Corcept’s cortisol modulator triggering setback / 2 months

Related Tags

---

StackHealth Time Machine

---